{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:56:13Z","timestamp":1753890973134,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Although bedaquiline has advanced the treatment of multidrug-resistant tuberculosis (TB), concerns remain about the cardiotoxic potential of this agent, albeit by unexplored mechanisms. Accordingly, we have investigated augmentation of the reactivity of human platelets <jats:italic>in vitro<\/jats:italic> as a potential mechanism of bedaquiline-mediated cardiotoxicity. Platelet-rich plasma (PRP) or isolated cells prepared from the blood of healthy, adult humans were treated with bedaquiline (0.625\u201310 \u00b5g\/ml), followed by activation with adenosine 5\u2019-diphosphate (ADP), thrombin or the thromboxane A<jats:sub>2<\/jats:sub> receptor agonist (U46619). Expression of platelet CD62P (P-selectin), platelet aggregation, Ca<jats:sup>2+<\/jats:sup> fluxes and phosphorylation of Akt1 were measured using flow cytometry, spectrophotometry, fluorescence spectrometry, and by ELISA procedures, respectively. Exposure to bedaquiline caused dose-related inhibition of ADP-activated, but not thrombin- or U46619-activated, expression of CD62P by platelets, achieving statistical significance at a threshold concentration of 5 \u00b5g\/ml and was paralleled by inhibition of aggregation and Ca<jats:sup>2+<\/jats:sup> mobilization. These ADP-selective inhibitory effects of bedaquiline on platelet activation were mimicked by wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI3-K), implicating PI3-K as being a common target of both agents, a contention that was confirmed by the observed inhibitory effects of bedaquiline on the phosphorylation of Akt1 following activation of platelets with ADP. These apparent inhibitory effects of bedaquiline on the activity of PI3-K may result from the secondary cationic amphiphilic properties of this agent. If operative <jats:italic>in vivo<\/jats:italic>, these anti-platelet effects of bedaquiline may contribute to ameliorating the risk of TB-associated cardiovascular disease, but this remains to be explored in the clinical setting.<\/jats:p>","DOI":"10.3389\/fimmu.2020.621148","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T07:25:47Z","timestamp":1614324347000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase"],"prefix":"10.3389","volume":"11","author":[{"given":"Gregory R.","family":"Tintinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette J.","family":"Theron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen C.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moloko C.","family":"Cholo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan G.","family":"Nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw426","article-title":"Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline","volume":"72","author":"Cholo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00060-17","article-title":"New approaches and therapeutic options for Mycobacterium tuberculosis in a dormant state","volume":"31","author":"Ca\u00f1o-Mu\u00f1iz","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"B4","unstructured":"Briefing Package, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA. NDA 204-384. Committee Meeting 2012, November 2012"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-013-0009-3","article-title":"A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis","volume":"2","author":"Fox","year":"2013","journal-title":"Infect Dis Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1039\/c6ob01060a","article-title":"Complexation of clofazimine by macrocyclic cucurbit[7]uril reduced its cardiotoxicity without affecting the antimycobacterial efficacy","volume":"14","author":"Li","year":"2016","journal-title":"Org Biomol Chem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01207-2016","article-title":"Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine","volume":"48","author":"Wallis","year":"2016","journal-title":"Eur Respir J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00724-2015","article-title":"the TMC207-C209 Study Group. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01552-2016","article-title":"Cardiac safety of extensively drug-resistant tuberculosis regiments including bedaquiline, delamanid and clofazimine","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12879-019-4197-7","article-title":"Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases","volume":"19","author":"Jones","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268817000279","article-title":"Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis","volume":"145","author":"Huaman","year":"2017","journal-title":"Epidemiol Infect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-83","article-title":"Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors","volume":"10","author":"Pepper","year":"2010","journal-title":"BMC Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000166521.90532.44","article-title":"New links between inflammation and thrombosis","volume":"25","author":"Wagner","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-017-2727-4","article-title":"Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease","volume":"371","author":"Lisman","year":"2018","journal-title":"Cell Tissue Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2010.00166","article-title":"Platelets and cardiac arrhythmia","volume":"1","author":"de Jong","year":"2010","journal-title":"Front Physiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI20267","article-title":"Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2","volume":"113","author":"Woulfe","year":"2004","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1586\/ehm.09.75","article-title":"Akt signaling in platelets and thrombosis","volume":"3","author":"Woulfe","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)83641-4","article-title":"A new generation of Ca2+ indicators with greatly improved fluorescence properties","volume":"260","author":"Grynkiewicz","year":"1985","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2018.1445838","article-title":"96-Well plate-based aggregometry","volume":"29","author":"Chan","year":"2018","journal-title":"Platelets"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706366","article-title":"Induction of central signalling pathways and select functional effects in human platelets by \u03b2-boswellic acid","volume":"146","author":"Poeckel","year":"2005","journal-title":"Br J Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-323204","article-title":"An important role for Akt3 in platelet activation and thrombosis","volume":"118","author":"O\u2019Brien","year":"2011","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12954","article-title":"Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet activation by inhibition of glycogen synthase kinase 3\u03b1\/\u03b2","volume":"13","author":"Moroi","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-07","article-title":"Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis","volume":"52","author":"Rustomjee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11373-005-9016-z","article-title":"PI3-kinase is essential for ADP-stimulated integrin alpha(IIb)beta3-mediated platelet calcium oscillation, implications for P2Y receptor pathways in integrin alpha(IIb)beta3-initiated signaling cross-talks","volume":"12","author":"Sun","year":"2005","journal-title":"J BioMed Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12952","article-title":"P2Y12 receptors: structure and function","volume":"13","author":"Cattaneo","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.19.11358","article-title":"Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation","volume":"270","author":"Kovacsovics","year":"1995","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0167-4889(99)00125-1","article-title":"A role for phosphatidylinositol 3-kinase in platelet aggregation in response to low, but not high, concentrations of PAF or thrombin","volume":"1452","author":"Lauener","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615690","article-title":"Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway","volume":"85","author":"Dangelmaier","year":"2001","journal-title":"Thromb Haemost"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.65.3.321","article-title":"Multiple roles for PI 3-kinase in the regulation of PLCgamma activity and Ca2+ mobilization in antigen-stimulated mast cells","volume":"65","author":"Barker","year":"1999","journal-title":"J Leukoc Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.37.23750","article-title":"Phosphoinositide 3-kinase regulates phospholipase Cgamma-mediated calcium signalling","volume":"273","author":"Rameh","year":"1998","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305077200","article-title":"A critical role for phospholipase Cgamma2 in alphaIIbbeta3-mediated platelet spreading","volume":"278","author":"Wonerow","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0534","article-title":"Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets","volume":"104","author":"Hardy","year":"2004","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01627","article-title":"The mycobacterial membrane: a novel target space for anti-tubercular drugs","volume":"9","author":"Chen","year":"2018","journal-title":"Front Microbiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.tube.2019.06.005","article-title":"A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity","volume":"117","author":"Patel","year":"2019","journal-title":"Tuberculosis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600252","article-title":"Characterisation of the binding of cationic amphiphilic drugs to phospholipid bilayers using surface plasmon resonance","volume":"2","author":"Nussio","year":"2007","journal-title":"Chem Med Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2007.06.023","article-title":"The relationship between the binding to and permeabilization of phospholipid bilayer membranes by GS14dfK4, a designed analog of the antimicrobial peptide gramicidin S","volume":"1768","author":"Abraham","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/srep18536","article-title":"Detachment of surface membrane invagination systems by cationic amphiphilic drugs","volume":"6","author":"Osman","year":"2016","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-018-0489-z","article-title":"Novel amphiphilic pyridinium ionic liquids-supported Schiff bases: ultrasound assisted synthesis, molecular docking and anticancer evaluation","volume":"12","author":"Al-Blewi","year":"2018","journal-title":"Chem Cent J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2913","article-title":"Clopidogrel (plavix)","volume":"32","author":"Comin","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31820b7c03","article-title":"The antimalarial drug mefloquine inhibits cardiac inward rectifier K+ channels: evidence for interference in PIP2-channel interaction","volume":"57","author":"L\u00f3pez-Izquierdo","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.246157","article-title":"Inhibition of the \u03b1-subunit of phosphoinositide 3-kinase in heart increases late sodium current and is arrhythmogenic","volume":"365","author":"Yang","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/19336950.2019.1697127","article-title":"PI3K\u03b1 in cardioprotection: Cytoskeleton, late Na + current, and mechanism of arrhythmias","volume":"13","author":"Zhabyeyev","year":"2019","journal-title":"Channels (Austin)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.621148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T07:25:59Z","timestamp":1614324359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.621148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2020.621148"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.621148","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"article-number":"621148"}}